Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 19Neoplasm Metastasis 5Triple Negative Breast Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2HER2-positive Breast Cancer 2Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumor 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Trastuzumab 19pyrotinib 14pertuzumab 8Docetaxel 7Paclitaxel 6Capecitabine 4Carboplatin 3neratinib 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2Ado-Trastuzumab Emtansine 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1palbociclib 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Goserelin 1Genetic Testing 1Fluorodeoxyglucose F18 1Enfuvirtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HER2-positive Breast Cancer × neratinib × Clear all
NCT07019272 2025-06-13

Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Hebei Medical University Fourth Hospital

Not yet recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

NCT06693024 2024-11-20

NeraHER2

Peking University People's Hospital

Recruiting
2,806 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡